Single BNT162b2 vaccine dose produces seroconversion in under 60 s cohort.
Single BNT162b2 vaccine dose produces seroconversion in under 60 s cohort.
复制标题
DOI：
10.1016/j.vaccine.2021.10.016
复制
发表时间：
2021-11-16
期刊：
影响因子：
5.5
通讯作者：
Halberthal M
中科院分区：
文献类型：
--
作者：
Shachor-Meyouhas Y;Hussein K;Szwarcwort-Cohen M;Weissman A;Mekel M;Dabaja-Younis H;Hyams G;Horowitz NA;Kaplan M;Halberthal M
2019冠状病毒病（COVID-19）大流行导致全球疫苗开发工作。2020年12月，辉瑞BNT 162 b2疫苗在美国获批。本研究描述了第一个BNT 162 b2疫苗剂量对大型队列的影响。这项回顾性研究检查了首次疫苗剂量对血清学的影响，并调查了血清转换与年龄或性别之间的关系。在首次接种疫苗后对1898名参与者进行了血清学血液检测; 81%的参与者在第21天接受第二次接种前进行了检测（平均年龄47.5 ± 12.45岁;中位数47.7岁，范围18-90岁）。在第21天的检测中，92.7%的检测结果为血清学阳性。总体阳性率为86.8%，1-14天内的阳性率从2.5%增加到89.8%（14-20天）、92.7%（21天）和95.9%（>21天）。首次给药后21天的平均抗体水平为64.3 ± 33.01 Au/ml（范围15-373 Au/ml，中位数61 Au/ml）。女性血清阳性率高于男性（88.3%）。vs83.3%，p < 0.001; OR 1.515; 95%CI 1.152-1.994）。年龄> 60岁与血清阳性可能性降低相关（p < 0.001; OR 0.926; 95%CI 0.911-0.940）。首次接种疫苗和血清学检测之间的时间较长与血清阳性可能性增加相关（p < 0.001; OR 1.350; 95% CI 1.298-1.404）。在< 60岁的个体中，第一剂BNT 162 b2接种后的高血清转化率可能证明延迟第二剂接种是合理的，可能有助于缓解全球疫苗供应短缺，使该人群能够在较短时间内接种两次疫苗，并最终减少COVID-19的传染。
The coronavirus disease 2019 (COVID-19) pandemic has led to worldwide vaccination development efforts. In December 2020 the Pfizer BNT162b2 vaccine was approved in the United States. This study describes the first BNT162b2 vaccine dose effect on a large cohort. This retrospective study examined first vaccine dose effect on serology and investigated the associations between seroconversion and age or sex. Serological blood tests were performed on 1898 participants following first vaccine dose; 81% were tested on day 21, before receiving the second dose (mean age 47.5 ± 12.45; median 47.7, range 18–90). Positive serology was found in 92.7% of day 21 tests. Overall positivity was 86.8%, with rates increasing from 2.5% within 1–14 days to 89.8% (14–20 days), 92.7% (21 days), and 95.9% (>21 days). Mean antibody levels 21 days after first dose were 64.3 ± 33.01 AU/ml, (range 15–373 AU/ml, median 61 AU/ml). Seropositivity was greater in females than males (88.3%. vs 83.3% respectively, p < 0.001; OR1.515; 95% CI 1.152–1.994). Older age > 60 years was associated with decreased likelihood of seropositivity (p < 0.001; OR 0.926; 95% CI 0.911–0.940). Longer time between first vaccination and serology tests was associated with increased likelihood for seropositivity (p < 0.001; OR 1.350; 95% CI 1.298–1.404). The high seroconversion rate following first BNT162b2 dose among individuals < 60 may justify delayed delivery of the second dose, potentially help relieve the worldwide vaccination supply shortage, enable vaccination of twice this population within a shorter period, and ultimately reduce COVID-19 contagion.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group
DOI：
10.1016/s1473-3099(10)70049-9
发表时间：
2010-05
期刊：
The Lancet. Infectious diseases
影响因子：
--
作者：
Klein SL;Jedlicka A;Pekosz A
通讯作者：
Pekosz A
影响因子：
64.8
作者：
Mulligan, Mark J.;Lyke, Kirsten E.;Jansen, Kathrin U.
通讯作者：
Jansen, Kathrin U.
影响因子：
4.9
作者：
Havlichek, D;Rosenman, K;Guss, P
通讯作者：
Guss, P